RAMON SANCHEZ: Open Payments
NPI 1063404408 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,650 in 126 payments from 17 companies in 2025. Trend: 2023 $2,008 · 2024 $2,474 · 2025 $2,650
Food & beverage: $2,628Education: $22
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $479 |
| Neurocrine BioSciences, Inc. | 17 | $438 |
| Otsuka America Pharmaceutical, Inc. | 16 | $288 |
| Vanda Pharmaceuticals Inc. | 16 | $277 |
| Teva Pharmaceuticals USA, Inc. | 9 | $213 |
| E.R. Squibb & Sons, L.L.C. | 12 | $199 |
| Axsome Therapeutics, Inc. | 10 | $175 |
| Janssen Pharmaceuticals, Inc | 4 | $126 |
| Lundbeck LLC | 6 | $113 |
| Alkermes, Inc. | 4 | $76 |
Products named: CAPLYTA, INGREZZA, FANAPT, COBENFY, REXULTI, ABILIFY ASIMTUFII, Auvelity, UZEDY.
Industry payments across TX — which companies pay providers there.
